⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methoxymethane SCHEMBL200385 | 0.91 | NOS1 (0.52) | — | |
| SCHEMBL14936408 | 0.79 | NOS1 (0.65) | — | |
| SCHEMBL5378534 | 0.77 | — | — | |
| SCHEMBL24062403 | 0.75 | — | — | |
| SCHEMBL31340016 | 0.75 | — | — | |
| SCHEMBL14385207 | 0.75 | — | — | |
| SCHEMBL15101304 | 0.75 | — | — | |
| SCHEMBL1868722 | 0.75 | — | — | |
| SCHEMBL881140 | 0.75 | — | — | |
| SCHEMBL12428566 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807063-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| WO-2006045799-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| US-20250026723-A1 | Cannabinoid Receptor Modulating Compounds | THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |